Page 41 - GPD-1-1

Gene & Protein in Disease Genetically engineered T cells in cancer immunotherapy

7. Ecsedi M, McAfee MS, Chapuis AG, 2021, The anticancer 19. Huang R, Li X, He Y, et al., 2020, Recent advances in CAR-T
potential of T cell receptor-engineered T cells. Trends cell engineering. J Hematol Oncol, 13(1): 86.
Cancer, 7(1): 48–56.
https://doi.org/10.1186/s13045-020-00910-5
https://doi.org/10.1016/j.trecan.2020.09.002
20. Shah NN, Lee DW, Yates B, et al., 2021, Long-term
8. Raes L, De Smedt SC, Raemdonck K, et al., 2021, Non-viral follow-up of CD19-CAR T-cell therapy in children
transfection technologies for next-generation therapeutic T and young adults with B-ALL. J Clin Oncol, 39(15):
cell engineering. Biotechnol Adv, 49: 107760. 1650–1659.
https://doi.org/10.1016/j.biotechadv.2021.107760 https://doi.org/10.1200/JCO.20.02262
9. Bailey SR, Maus MV, 2019, Gene editing for immune cell 21. Chong EA, Ruella M, Schuster SJ, 2021, Lymphoma program
therapies. Nat Biotechnol, 37(12): 1425–1434. investigators at the university of P: Five-year outcomes for
refractory B-Cell lymphomas with CAR T-Cell therapy.
https://doi.org/10.1038/s41587-019-0137-8
N Engl J Med, 384(7): 673–674.
10. Kuwana Y, Asakura Y, Utsunomiya N, et al., 1987, Expression
of chimeric receptor composed of immunoglobulin-derived https://doi.org/10.1056/NEJMc2030164
V regions and T-cell receptor-derived C regions. Biochem 22. Wang M, Munoz J, Goy A, et al., 2020, KTE-X19 CAR T-cell
Biophys Res Commun, 149(3): 960–968. therapy in relapsed or refractory mantle-cell lymphoma.
N Engl J Med, 382(14): 1331–1342.
https://doi.org/10.1016 / 0006-291x(87)90502-x
https://doi.org/10.1056/NEJMoa1914347
11. Wilkins O, Keeler AM, Flotte TR, 2017, CAR T-Cell therapy:
Progress and prospects. Hum Gene Ther Methods, 28(2): 23. Ramos CA, Grover NS, Beaven AW, et al., 2020, Anti-CD30
61–66. CAR-T cell therapy in relapsed and refractory hodgkin
lymphoma. J Clin Oncol, 38(32): 3794–3804.
https://doi.org/10.1089/hgtb.2016.153
https://doi.org/10.1200/JCO.20.01342
12. Kochenderfer JN, Feldman SA, Zhao Y, et al., 2009,
Construction and preclinical evaluation of an anti-CD19 24. Raje N, Berdeja J, Lin Y, et al., 2019, Anti-BCMA CAR T-cell
chimeric antigen receptor. J Immunother, 32(7): 689–702. therapy bb2121 in relapsed or refractory multiple myeloma.
N Engl J Med, 380(18): 1726–1737.
https://doi.org/10.1097/CJI.0b013e3181ac6138
https://doi.org/10.1056/NEJMoa1817226
13. Zhang C, Liu J, Zhong JF, et al., 2017, Engineering CAR-T
cells. Biomark Res, 5: 22. 25. Neelapu SS, Tummala S, Kebriaei P, et al., 2018, Chimeric
antigen receptor T-cell therapy assessment and management
https://doi.org/10.1186/s40364-017-0102-y
of toxicities. Nat Rev Clin Oncol, 15(1): 47–62.
14. Jacobson CA, Chavez JC, Sehgal AR, et al., 2022,
Axicabtagene ciloleucel in relapsed or refractory indolent https://doi.org/10.1038/nrclinonc.2017.148
non-Hodgkin lymphoma (ZUMA-5): A single-arm, 26. Grover P, Veilleux O, Tian L, et al., 2022, Chimeric
multicentre, phase 2 trial. Lancet Oncol, 23(1): 91–103. antigen receptor T-cell therapy in adults with B-cell acute
lymphoblastic leukemia. Blood Adv, 6(5): 1608–1618.
https://doi.org/10.1016/S1470-2045(21)00591-X
https://doi.org/10.1182/bloodadvances.2020003482
15. Sterner RC, Sterner RM, 2021, CAR-T cell therapy: Current
limitations and potential strategies. Blood Cancer J, 11(4): 69. 27. Shah BD, Bishop MR, Oluwole OO, et al., 2021, KTE-X19
anti-CD19 CAR T-cell therapy in adult relapsed/refractory
16. Guercio M, Manni S, Boffa I, et al., 2021, Inclusion of the
inducible caspase 9 suicide gene in CAR construct increases acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
safety of CAR.CD19 T cell therapy in B-Cell malignancies. Blood, 138(1): 11–22.
Front Immunol, 12: 755639. https://doi.org/10.1182/blood.2020009098
https://doi.org/10.3389/fimmu.2021.755639 28. Samur MK, Fulciniti M, Samur AA, et al., 2021, Biallelic
loss of BCMA as a resistance mechanism to CAR T cell
17. Spiegel JY, Patel S, Muffly L, et al., 2021, CAR T cells with
dual targeting of CD19 and CD22 in adult patients with therapy in a patient with multiple myeloma. Nat Commun,
recurrent or refractory B cell malignancies: A phase 1 trial. 12(1): 868.
Nat Med, 27(8): 1419–1431. https://doi.org/10.1038/s41467-021-21177-5
https://doi.org/10.1038/s41591-021-01436-0 29. Shah NN, Fry TJ, 2019, Mechanisms of resistance to CAR T
cell therapy. Nat Rev Clin Oncol, 16(6): 372–385.
18. van der Schans JJ, van de Donk N, Mutis T, 2020, Dual
targeting to overcome current challenges in multiple https://doi.org/10.1038/s41571-019-0184-6
myeloma CAR T-cell treatment. Front Oncol, 10: 1362.
30. Brudno JN, Kochenderfer JN, 2019, Recent advances in
https://doi.org/10.3389/fonc.2020.01362 CAR T-cell toxicity: Mechanisms, manifestations and

Volume 1 Issue 1 (2022) 10 https://doi.org/10.36922/gpd.v1i1.114